REG - Genedrive PLC - New interactive investor hub

GenedriveAnnouncement

Thu 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK1846La&default-theme=true

RNS Number : 1846L  Genedrive PLC  11 December 2025

genedrive plc

("genedrive" or the "Company")

 

genedrive plc launches new interactive investor hub

 

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company,
is pleased to announce the launch of our interactive investor hub. For both
existing and prospective shareholders, over time the new investor hub will
bring all genedrive content into a single integrated platform to better inform
and engage with investors and stakeholders.

 

The investor hub provides an interactive online experience allowing genedrive
stakeholders to comment on and ask the genedrive team questions via a portal
which will be monitored and responded to as timely as possible.

 

How to sign up for the genedrive investor hub:

 

1.    Visit investors.genedrive.com (http://investors.genedrive.com)

2.    Follow the prompts to sign up for an investor hub account

3.    Complete your account profile

 

Dr Gino Miele, CEO of genedrive plc, said: "Open and transparent communication
with our shareholders is essential, particularly in a fast-moving environment
like ours. Whilst RNS remains the first source of regulated news on genedrive,
the investor hub gives us a direct channel to share accurate information and
meaningful updates straight from the company ensuring investors hear from us
directly.  The hub enables shareholders to submit questions, receive updates,
and engage directly with the Company. We encourage all investors to register
and use the hub as their central source for trusted updates, insights, and
dialogue with our team."

 

Engage with the genedrive management team directly by asking questions,
watching video
summaries and seeing what other shareholders have to say.
Navigate to our Interactive Investor
hub here:
https://investors.genedrive.com/link/PZ3d7y
(https://investors.genedrive.com/link/PZ3d7y)

 

For further information, please contact:

 

 Genedrive plc                                     https://investors.genedrive.com/s/e0025c

                                                 (https://investors.genedrive.com/s/e0025c)
 Dr Gino Miele (CEO)

                                                 +44 (0) 161 989 0245
 Russ Shaw (CFO)

 We encourage all investors to share questions

 on this announcement via our investor hub

                                                     +44 (0) 20 7148 8900

 Peel Hunt LLP - Nominated Adviser, Joint Broker

 James Steel
 Walbrook PR Ltd (Media & Investor Relations)      https://investors.genedrive.com/s/e0025c

                                                 (https://investors.genedrive.com/s/e0025c)
 Anna Dunphy

                                                   +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)

                                                   +44 (0)7876 741 001

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
(https://investors.genedrive.com/s/efea03)

 

 

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) )

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS. The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUAUWRVBUUARA



            Copyright 2019 Regulatory News Service, all rights reserved